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0022-2836/$ - see front matter © 2008 EThe heat shock protein Hsp104 has been reported to possess the ability to
modulate protein aggregation and toxicity and to “catalyze” the disag-
gregation and recovery of protein aggregates, including amyloid fibrils, in
yeast, Escherichia coli, mammalian cell cultures, and animal models of
Huntington's disease and Parkinson's disease. To provide mechanistic
insight into the molecular mechanisms by which Hsp104 modulates
aggregation and fibrillogenesis, the effect of Hsp104 on the fibrillogenesis
of amyloid beta (Aβ) was investigated by characterizing its ability to
interfere with oligomerization and fibrillogenesis of different species along
the amyloid-formation pathway of Aβ. To probe the disaggregation activity
of Hsp104, its ability to dissociate preformed protofibrillar and fibrillar
aggregates ofAβwas assessed in the presence and in the absence of ATP.Our
results show that Hsp104 inhibits the fibrillization of monomeric and
protofibrillar forms of Aβ in a concentration-dependent but ATP-indepen-
dent manner. Inhibition of Aβ fibrillization by Hsp104 is observable up to
Hsp104/Aβ stoichiometric ratios of 1:1000, suggesting a preferential inter-
action of Hsp104 with aggregation intermediates (e.g., oligomers, proto-
fibrils, small fibrils) on the pathway of Aβ amyloid formation. This hypo-
thesis is consistent with our observations that Hsp104 (i) interacts with Aβ
protofibrils, (ii) inhibits conversion of protofibrils into amyloid fibrils, (iii)
arrests fibril elongation and reassembly, and (iv) abolishes the capacity of
protofibrils and sonicated fibrils to seed the fibrillization of monomeric Aβ.
Together, these findings suggest that the strong inhibition of Aβ fibrillization
by Hsp104 is mediated by its ability to act at different stages and target
multiple intermediates on the pathway to amyloid formation.© 2008 Elsevier Ltd. All rights reserved.Keywords: amyloid formation Aβ; Hsp104; disaggregation; Alzheimer's
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Several neurodegenerative diseases are caused
by protein misfolding and the accumulation of
toxic aggregates in the cytoplasm (e.g., Lewy
bodies in Parkinson's disease) or in the extracel-
lular space (e.g., amyloid plaques in Alzheimer's
disease) of neurons.1 The ability of molecular
chaperones to prevent protein misfolding and
block or reverse protein aggregation-induced toxi-
city in vitro and in vivo has led to the hypothesis
that some members of the chaperone system might
play an active role in the disaggregation and
clearance of amyloid fibrils in vivo. Moleculard.
1158 Hsp104 Suppresses Amyloid Formation of Ahchaperones function, either individually or in
concert with other chaperones, to ensure the
proper folding of newly synthesized polypeptides
and the correct refolding of aggregation prone non-
native states that would otherwise proceed to form
amyloid fibrils. Amongst the different classes of
molecular chaperones, only the yeast heat shock
protein Hsp104 has been described to possess an
amyloid–disaggregase activity, the ability to
reverse fibril formation in vitro.2,3 Hsp104 and its
prokaryotic homologue ClpB are hexameric AAA+
ATPases with two nucleotide-binding domains
(NBDs) per subunit that couple asymmetric cycles
of ATP hydrolysis to the disaggregation of their
polypeptide substrates. The substrate binding of
ClpB/Hsp104 was shown to be dependent on the
ATP state (Scheme 1a); accordingly, reduced or
impaired ATP hydrolysis, as in the case of theScheme 1. High-affinity substrate binding by Hsp104 is d
substrate binding cycle of Hsp104WT. During steady-state ATP
conformational states: an ADP-bound state with a low affinity
with a high affinity towards polypeptides. Accordingly, subs
Hsp104–ATP–substrate complex (left side). The ternary comp
fication from Ref. 4. (b) ATP turnover by Hsp104WT and Hsp10
during steady-state ATP hydrolysis. However, tight substrate
slowing down ATP hydrolysis improves substrate binding of H
the catalytic residues of Hsp104 are mutated; therefore, a perm
when ATP is present.5,6 (c) Hsp104 might interact with differen
aggregation of monomers, oligomers, protofibrils and fibrils oATPase mutant E285Q/E687Q (Hsp104TRAP), inc-
reases the affinity towards polypeptide subs-
trates5,7,8 (Scheme 1b). The processing of poly-
peptides by wild-type ClpB/Hsp104 results in the
unfolding of non-native structures and separation
of single polypeptides from aggregates, thus faci-
litating the refolding of proteins.5,9,10 Several lines
of evidence suggest that ClpB/Hsp104, in combi-
nation with the Hsp70/40 chaperone system,
constitutes an efficient protein disaggregation
machinery in bacteria, plants, and fungi, but not
in metazoans.4,11,12 In these organisms, ClpB/
Hsp104 is directly involved in the disaggregation
of stable protein aggregates after heat shock, and
Hsp104 plays a central role in prion propagation of
yeast cells.13–15 Overexpression of Hsp104 reduces
the aggregation and toxicity of mutant polygluta-
mine (polyQ) in animal models [polyQ is related toependent on its nucleotide state. (a) The ATPase-coupled
hydrolysis, the NBD1 of Hsp104 cycles between different
towards polypeptide substrates and an ATP-bound state
trates bind to the ATP state, thereby generating a ternary
lex is committed to ATP hydrolysis. Adapted with modi-
4TRAP. Hsp104WT cycles between different nucleotide states
binding requires a (longer) ATP presence at NBD1. Thus,
sp104. No ATP hydrolysis takes place in the Trap mutant:
anent high-affinity state for substrate interaction is found
t species on the pathway of fibrillization and/or delay the
f Aβ.
Fig. 1. Hsp104 prevents amyloid fibril formation of monomeric Aβ. (a) ThT fluorescence at different time points of
aggregation of monomeric Aβ alone (I), Aβ with Hsp104WT (II), Aβ with Hsp104WT in the presence of ATP (III), Aβ only
in the presence of ATP (IV), Aβ with Hsp104TRAP in the presence of ATP (V), and Aβ with Hsp104WT in the presence of
ATPγS (VI). (b) SDS-PAGE analysis of the soluble fraction of the samples at the beginning (0 h) and at the end (96 h) of the
experiment. The average fluorescence data from triplicate samples and standard deviation are plotted. (c) TEM images of
the different samples at 96 h. The scale bar represents 200 nm. (d) Detailed view of the Hsp104 molecules in the samples at
96 h. The scale bar represents 40 nm.
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1160 Hsp104 Suppresses Amyloid Formation of AhHuntington's disease (HD)], mammalian cell cul-
tures, and yeast models of HD.16–20 Others have
shown that Hsp104 alone can disassemble pre-
formed Sup35 and Ure2 prion fibrils.2,3 However,
the molecular mechanisms underlying these effects
remain poorly understood (Scheme 1c). It is
noteworthy that in all the studies mentioned
above it is not possible to discern whether the
effects of Hsp104 are mediated by its unfoldase/
disaggregase activity or simply through direct
interactions with the monomeric or aggregated
forms of the substrate.
The ability of Hsp104 to modulate the aggregation
of different amyloid-forming proteins [e.g., polyQ,
prion protein (PrP), Sup35, Ure2]3,20–23 suggests that
it recognizes a common structural motif that is
shared by the monomeric and/or aggregated forms
of these proteins. To provide mechanistic insight
into the molecular mechanism by which Hsp104
modulates protein aggregation and fibrillogenesis,
we investigated the effect of Hsp104 on the
oligomerization and fibril formation of the highly
amyloidogenic peptide amyloid beta-(1–42) (Aβ42)
as a model substrate. Aβ peptide is the main
constituent of amyloid plaques and plays a central
role in the pathogenesis of Alzheimer's disease.
Aβ42 was chosen in particular because of its very
well defined aggregation kinetics and the ease with
which protofibrils and fibrils of Aβ42 can be
reproducibly prepared in high quantities.24,25
Using an array of biophysical methods, we char-
acterized the ability of Hsp104 to interact with the
different intermediate species along the amyloid-
formation pathway (Scheme 1c) and the conse-
quences of these interactions on the fibrillization of
Aβ. To probe the disaggregation activity of Hsp104,
its ability to dissociate preformed aggregates of Aβ
or block the seeding capacity of protofibrillar andFig. 2. Hsp104 hinders the aggregation of monomeric Aβ i
fluorescence at different time points of the aggregation proce
0.01 μM (III), 0.02 μM (IV), 0.1 μM (V), and 1 μM (VI) of Hsp10
from triplicate samples and standard deviations are plotted. (b
at the beginning (0 h) and after 10 days of incubation. (c) TEMfibrillar Aβ was tested in the presence and in the
absence of ATP (Scheme 1c). Together, our studies
demonstrate that Hsp104 targets multiple inter-
mediates on the amyloid pathway and suppresses
the seeding capacity of Aβ fibrils and protofibrils.
These studies shed new light on the molecular
mechanisms by which Hsp104 modulates the
aggregation and fibrillogenesis of amyloid-forming
proteins in general.Results
Hsp104 prevents amyloid fibril formation of
monomeric Aβ
To probe the ability of Hsp104 to interfere with the
aggregation of monomeric Aβ as well as the ATP
dependency of this process, 10 μM of freshly isolated
Aβ monomer was co-incubated with 1 μM of wild-
type Hsp104 (Hsp104WT) in the presence and absence
of nucleotides. The aggregation process was mon-
itored by thioflavin T (ThT) fluorescence, SDS-PAGE
analysis, and transmission electron microscopy
(TEM) at different time points. Aβ incubated alone
showed a marked increase in ThT fluorescence
within the first 24 h of incubation, after which the
ThT values remained unchanged (Fig. 1a-I). When
Hsp104WT was added to monomeric Aβ, the ThT
values were similar to those of non-aggregated Aβ
and remained unchanged during the course of the
experiment (see 96 h in Fig. 1a-II), suggesting an
Hsp104-mediated inhibition of Aβ fibrillization.
Figure 1a-III shows that the presence of ATP did
not enhance or reduce Hsp104-mediated inhibition of
Aβ fibrillogenesis. The control sample with Aβ and
ATP in the absence of Hsp104 (Fig. 1a-IV) exhibitedn a specific and concentration-dependent manner. (a) ThT
ss of monomeric Aβ alone (I), Aβ with ATP (II), Aβ with
4WT in the presence of ATP. The average fluorescence data
) SDS-PAGE analysis of the soluble fraction of the samples
images of the samples at different time points.
Fig. 2 (legend on previous page)
1161Hsp104 Suppresses Amyloid Formation of Ah
1162 Hsp104 Suppresses Amyloid Formation of Ahthe same ThT pattern over time as the control sample
containing onlyAβ. To determinewhether enhancing
the interaction of Hsp104 with monomeric Aβ could
increase its capacity to block Aβ oligomerization and
fibrillogenesis, we artificially induced a high-affinity
state of Hsp104 for the polypeptide by using two
different strategies: (i) replacing the wild-type
(Hsp104WT) by the Trap mutant of Hsp104 (Hsp104-
TRAP) and (ii) adding adenosine-5β-O-(3-thiotripho-
sphate) (ATPγS). Hsp104TRAP contains two point
mutations that render the chaperone unable to hydro-
lyze ATP (Scheme 1a and b).4 On the other hand,
ATPγS is an analogue of ATP that is hardly hydro-
lyzed by Hsp104.5 In both cases, when Hsp104TRAP is
used with ATP or Hsp104WT with ATPγS, the non-Fig. 3. Hsp104 prevents conversion of Aβ protofibrils in
tofibrils. The scale bar represents 200 nm. (b) ThT fluorescen
protofibrils (PFs) alone (I), PFs with Hsp104WT (II), PFs w
fluorescence data from triplicate samples and standard deviat
72 h. The scale bar represents 200 nm. III in (b) shows the inte
scale bar represents 40 nm. (d) SDS-PAGE analysis of the soluhydrolyzed nucleotide remains bound to the chaper-
one, inducing a permanent high-affinity state for the
substrate (Scheme 1a).4 Aβ samples containing
Hsp104TRAP in the presence of ATP as well as
samples containing Hsp104WT with ATPγS did not
show fibril formation, as demonstrated by the
significant reduction in ThT values.
In order to quantify the remaining soluble protein
(monomers, oligomers, and protofibrils), the sam-
ples were analyzed by SDS-PAGE. Aliquots of the
different samples were centrifuged to remove inso-
luble material and the supernatant was subjected to
gel electrophoresis. Figure 1b shows the level of
soluble protein at the beginning (0 h) and at the
end (96 h) of the aggregation procedure for eachto mature fibrils. (a) TEM image of freshly isolated pro-
ce at different time points of the aggregation process of
ith Hsp104TRAP in presence of ATP (III). The average
ion are plotted. (c) TEM images of the different samples at
raction of Hsp104TRAP with protofibrils in sample III. The
ble fraction of the samples at different time points.
1163Hsp104 Suppresses Amyloid Formation of Ahsample. All samples containing Hsp104 showed
that significant amounts of soluble Aβ (monomers
and protofibrils) remain in the supernatant after
96 h of incubation. In contrast, samples containing
Aβ alone or Aβ with ATP did not show any band
corresponding to Aβ after 96 h of incubation at
37 °C, suggesting that almost all soluble Aβ has
been converted into insoluble fibrils under these
conditions. The reduced intensity of the Aβ bands
at 96 h is due to staining artifact in this specific
case and does not reflect reduced levels of soluble
Aβ (see Figs. 2, 3, and 4). In agreement with the
ThT data, the TEM images at 96 h showed dense
networks of fibrils in samples of Aβ alone or Aβ
with ATP (Fig. 1c-I and -IV). In contrast, samples
containing Hsp104 did not show mature fibrils but
rather some Aβ oligomers and protofibrils (Fig. 1c-
II, -III, -V, and -VI). This observation was not
dependent on the Hsp104 variant or the presence/
absence of nucleotide. In the samples containing
ATP, we observed predominantly spherical, ring-
like structures, which presumably correspond to
hexameric Hsp104 molecules (Fig. 1c-II, -III, -V, -VI,Fig. 4. Hsp104 abolishes the seeding capacity of fibrillar
aggregation process of Aβ monomer alone (I), Aβ monomer
2.2 μM SFs in the presence of Hsp104WT (III), and monom
fluorescence data from triplicate samples and standard dev
fraction of the samples at 72 h. (c) TEM images of samples IIIand d). When Hsp104 was incubated in the
absence of Aβ, we did not observe any aggregation
or fibril formation (see Hsp104 alone in Supple-
mentary Fig. S1). In summary, Hsp104 blocks the
fibrillization, but not the oligomerization, of Aβ.
The inhibitory effect of Hsp104 is independent of
the presence of nucleotides or of the nucleotide-
binding capacity of Hsp104.
Hsp104 inhibits the fibrillization of monomeric
Aβ in a specific and concentration-dependent
manner
In order to evaluate the effect of Hsp104 concen-
tration on Aβ, the kinetics of Aβ aggregation was
analyzed in the presence of ATP at different Hsp104
concentrations. Since we did not observe any fibril
formation at an Hsp104 concentration of 1 μM (at
least up to 96 h of incubation), lower concentrations
of Hsp104WT were explored (Fig. 2). The control
sample containing only Aβ showed the character-
istic sigmoid ThT fluorescence curve (Fig. 2a-I) with
a lag phase (0–9 h) followed by a rapid increase inAβ. (a) ThT fluorescence at different time points of the
seeded with 2.2 μM SFs (II), Aβ monomer seeded with
eric Aβ in the presence of Hsp104WT (IV). The average
iation are plotted. (b) SDS-PAGE analysis of the soluble
and IV at 72 h. The scale bars represents 100 nm.
1164 Hsp104 Suppresses Amyloid Formation of Ahthe ThT signal (9–24 h) before a plateau was reached.
Similar aggregation kinetics were observed in the
presence of ATP (Fig. 2a-II). A concentration-
dependent delay of Aβ aggregation was found in
the range of 0.01 to 1 μMHsp104. In the presence of
0.01 μM Hsp104, a significant delay in the lag
phase was observed when compared to the control,
i.e., the ThT fluorescence started to rise after 72 h
(Fig. 2a-III) instead of a lag time of 9 h for the control
sample. When the Hsp104 concentration was
increased to 0.02 μM, the lag phase extended to ∼6
days (144 h, Fig. 2a-IV). This delay was increased to
∼8 and N12 days at Hsp104 concentrations of 0.1
(Fig. 2a-V) and 1 μM (Fig. 2a-VI), consistent with a
concentration-dependent inhibition of Aβ fibrilliza-
tion by Hsp104. Figure 2b shows the SDS-PAGE
analysis of Aβ samples in the presence of increasing
concentrations of Hsp104 at the beginning and after
10 days of aggregation. After incubation for 10 days,
samples containing monomeric Aβ alone, Aβ with
ATP, or Aβ with either 0.01 or 0.02 μM Hsp104
showed almost no Aβ monomer in the supernatant
fraction. Samples with higher amounts of Hsp104,
0.1 and 1 μM, showed a band of Aβ of the same
intensity as in the time-zero lanes, consistent with
the ThT results. TEM images of the samples at
different time points are shown in Fig. 2c. Samples
without Hsp104, such as Aβ alone or Aβ with ATP,
showed predominant bundles of mature fibrils
already after 24 h (Fig. 2c-I, -II). However, samples
containing Hsp104, regardless of their concentra-
tion, showed almost no fibrillar structures but small
and amorphous aggregates (Fig. 2c-III to -VI). After
6 days of incubation, the sample with the lowest
concentration of Hsp104 (0.01 μM) contained some
disperse bundles of mature fibrils (Fig. 2c-III), while
the sample with 0.02 μMHsp104 showed quite long
but isolated fibrils (Fig. 2c-IV). At concentrations of
0.1 or 1 μM Hsp104 (Fig. 2c-V, -VI), very few fibrils
were observed. After 10 days of incubation, all
samples showed the presence of dense networks of
fibrils, except for those containing 0.1 or 1 μM
Hsp104. Samples containing 0.1 μMHsp104 showed
some long dispersed fibrils (Fig. 2c-V) and in the
sample containing 1 μM Hsp104 very few fibrillar
species were observed (Fig. 2c-VI).
Hsp104 prevents conversion of Aβ protofibrils
into fibrils
Protofibrils are intermediate species that precede
amyloid fibril formation in the aggregation pathway
of Aβ.26–28 The term protofibrils refers to a complex
mixture of species of heterogeneous size and
morphology, including spheres, pore-like structures,
and chain-like species.24 Protofibrils are on-pathway
intermediates and convert into mature amyloid
fibrils.26,29–31 To probe the ability of Hsp104 to
interact with these structures and to determine the
consequences of such interactions on the stability
and fibrillization of protofibrils, freshly isolated
protofibrils (Fig. 3a) were co-incubated with
Hsp104 and the aggregation was monitored byThT fluorescence, TEM, and SDS-PAGE. Upon
incubation at 37 °C, the sample containing proto-
fibrils alone showed a gradual increase in ThT signal
with time (Fig. 3b-I), consistent with a conversion of
the protofibrils into mature fibrils. However, co-
incubation of the same structures with Hsp104WT
inhibited fibrillization even after 6 days of incuba-
tion (Fig. 3b-II). A similar effect was observed when
protofibrils were incubated with Hsp104TRAP
together with ATP (Fig. 3b-III). In all cases, no
change in ThT signal was observed, suggesting that
a dissociation of the protofibrils did not take place,
at least not under the experimental conditions that
were used here. Consistent with this hypothesis,
TEM analysis of the samples containing either
Hsp104WT or Hsp104TRAP showed only some iso-
lated short fibrils but mainly protofibrillar structures
similar to those present at the starting conditions
(Fig. 3c-II, -III). As expected, samples containing
protofibrils alone showed dense networks of fibrils
after 72 h of incubation (Fig. 3c-I). Interestingly, in
the sample containing the TRAP mutant, some
ringlike structures, most likely Hsp104 molecules,
were found to be interacting with the protofibrils
(Fig. 3c-III-b, see also Fig. 1d-V). This could be due to
the stabilized hexamerization state and increased
affinity of the Hsp104TRAP for the substrate.
4 To
confirm the ThT and TEM results, an SDS-PAGE
analysis was performed to quantify the remaining
amount of soluble Aβ species (monomers, oligo-
mers, and protofibrils) at different time points (Fig.
3d). Aβ protofibrils generated with our protocol are
SDS sensitive and run as a band corresponding to
monomeric Aβ. In the absence of Hsp104, a sig-
nificant decrease in the amount of soluble Aβ was
observed over time. However, protofibril samples
containing either Hsp104WT or Hsp104TRAP showed
no change in the Aβ band intensity throughout the
experiment, in agreement with the ThT and TEM
data.
Hsp104 abolishes the seeding capacity of
fibrillar Aβ
To further characterize the possible interaction of
Hsp104 with the small aggregates or nuclei on the
amyloid pathway of Aβ, the ability of Hsp104 to
enhance or inhibit the seeding capacity of Aβ fibrils
was investigated. It is well established that the
addition of aggregation nuclei (preformed fibril
“seeds”) at the beginning of the process accelerates
fibril formation and abolishes the characteristic lag
phase.32,33 To create effective Aβ seeds, mature Aβ
fibrils were mechanically disrupted by sonication to
yield a narrow distribution of short fibrils, herein-
after referred to as sonicated fibrils (SFs). These
seeds did not reassociate to mature fibrils at low
concentrations (2.2 μM) within the time frame of the
experiments (Supplementary Fig. S2). Monomeric
Aβ fibrillization showed the typical sigmoid ThT
fluorescence curve (Fig. 4a-I). As expected, addition
of small amounts of fibrillar seeds (SFs) abolished
the lag phase and accelerated Aβ fibrillization (Fig.
1165Hsp104 Suppresses Amyloid Formation of Ah4a-II); notably, due to the ThT binding of SF, the ThT
baseline signal at t=0 h was slightly higher in the
samples in Fig. 4a-II and -III. Interestingly, addition
of Hsp104WT to the mixture of monomeric Aβ with
SFs abolished the seeding effect (Fig. 4a-III). TEM
images of the samples at 72 h displayed dense
networks of short fibrils when no Hsp104 was
present, whereas the seeded Aβ sample with
Hsp104WT showed predominantly spherical struc-
tures (Fig. 4c-III). When Hsp104 was added to the
sample containing only Aβ monomer, no fibril
formation was observed (Fig. 4c-IV). Moreover,
when Hsp104 was added to the SFs alone, without
Aβ monomer, no decrease in the ThT signal was
observed within the duration of the experiment
(Supplementary Fig. S2), ruling out any disaggrega-
tion of these structures by Hsp104. SDS-PAGE
analysis of these samples after 72 h incubation
(Fig. 4b) revealed that some soluble forms of Aβ
(monomers and proteofibrils) persist in the samples
containing Hsp104, whereas no soluble Aβ could be
detected in the supernatant of samples lacking
Hsp104 (Fig. 4b-III and -IV), which is in good
agreement with the ThT data. These results suggest
that Hsp104 abolishes the seeding capacity of
fibrillar Aβ.
Hsp104 abolishes the seeding by Aβ protofibrils
Protofibrils can also be used to seed the aggrega-
tion of Aβ.25 To probe the effect of Hsp104 on theseeding ability of Aβ protofibrils, a seeded aggrega-
tion assay with 10 μM protofibrils was carried out in
the presence and in the absence of Hsp104. When
monomeric Aβ was incubated for 96 h with 10 μM
protofibrils, the ThT signal reached values that were
approximately two times higher than those observed
for Aβ protofibrils alone and the lag phase was
significantly shortened (Fig. 5a-II versus a-I). Co-
incubation of Aβ monomer and protofibrils with
Hsp104 significantly reduced their seeding capacity
(Fig. 5a-III). Figure 5b shows that addition of Hsp104
to a mixture of monomeric Aβ and protofibrils
resulted in the accumulation of predominantly
protofibrillar aggregates and some short flexible
fibrillar structures (Fig. 5b-III). These structures
differed significantly from the corresponding sample
lacking Hsp104 (Fig. 5b-II) and suggest that Hsp104
also abolishes the seeding ability of protofibrillar Aβ,
possibly via direct interactions with either Aβ
protofibrils or monomers or both.
Hsp104 prevents further association of mature
Aβ fibrils
Hsp104 has been reported to possess the unique
ability of disrupting and resolubilizing stable pro-
tein aggregates.2,3 To probe the ability of Hsp104 to
disaggregate amyloid fibrils, Hsp104WT was incu-
bated with preformed mature Aβ fibrils. Since Aβ
has a strong propensity to form highly compact
networks of fibrils (Fig. 1c-I), which could reduceFig. 5. Hsp104 abolishes the
seeding of monomeric Aβ by pro-
tofibrils. (a) ThT fluorescence at
different time points of the aggre-
gation process of PFs alone (I), Aβ
monomer seeded with PFs (II), and
Aβ monomer seeded with PFs in
the presence of Hsp104WT (III). The
average fluorescence data from
triplicate samples and standard
deviation are plotted. (b) TEM
images of samples II and III at 24 h.
1166 Hsp104 Suppresses Amyloid Formation of Ahthe accessibility to Hsp104, Aβ fibrils were soni-
cated to generate short fibrils with a narrow size
distribution (Fig. 6c). The SFs were incubated in the
presence and in the absence of Hsp104WT and ATP.
To ensure the continuous supply of ATP throughout
the incubation process, an ATP-regenerating system
composed of pyruvate kinase (PK) and phospho-
enolpyruvate (PEP) was included. The sample
containing SFs with Hsp104 and ATP/PK/PEP
showed a low ThT fluorescence that remained
unchanged during the experiment (Fig. 6a-II). This
ThT signal was lower than the signal of the control
sample lacking Hsp104 and ATP/PK/PEP at the
start of the experiment. To check whether this
difference in ThT fluorescence at t=0 h was due to
an initial Hsp104-induced dissociation of pre-
formed fibrils or due to interference with ThT
fluorescence by the ATP-regenerating system, SFs
were incubated with ATP/PK/PEP in the absence
of Hsp104 (Fig. 6a-III). The addition of the ATP-
regenerating system to SFs also resulted in an initial
decrease in the ThT signal, suggesting an inter-
ference with the ThT fluorescence. Although this
sample showed significantly lower ThT valuesFig. 6. Hsp104 prevents further aggregation of mature Aβ
aggregation process of 10 μM sonicated mature fibrils (SFs) alo
PK/PEP (II), and 10 μM SFs only in the presence of ATP/PK
samples and standard deviations are plotted. (b) SDS-PAGE an
end of the experiment. (c) TEM image of the starting preparatio
of the different samples at 96 h. The scale bars represents 200compared to the controls with only SFs, a contin-
uous increase in the ThT signal was observed over
time, suggesting that the presence of the ATP-
regenerating system does not interfere with the
reassociation of mature fibrils. To check for any
disaggregation of the mature fibrils by Hsp104, we
determined the amount of soluble Aβ in the
samples at the end of the experiment by centrifuga-
tion and SDS-PAGE analysis of the supernatant
(Fig. 6b). In all samples, no soluble Aβ was
detected, suggesting that Hsp104 does not induce
the dissociation of preformed fibrils into monomers
or other soluble species. To verify these findings, all
samples were examined using TEM. The starting SF
material showed short and evenly distributed fibrils
throughout the grid (Fig. 6c). After 96 h, the
samples containing SFs alone, or SFs in the presence
of ATP/PK/PEP but without Hsp104, exhibited
large networks of fibrils (Fig. 6d-I and -III). Interes-
tingly, SFs incubated in the presence of Hsp104WT
and ATP/PK/PEP were lacking mature fibrils but
contained predominantly short fibrils decorated
with spherical structures, presumably Hsp104 hex-
amers (Fig. 6d-II).fibrils. (a) ThT fluorescence at different time points of the
ne (I), 10 μM SFs with Hsp104WT in the presence of ATP/
/PEP (III). The average fluorescence data from triplicate
alysis of the soluble fraction of the different samples at the
n of SFs. The scale bar represents 100 nm. (d) TEM images
nm.
1167Hsp104 Suppresses Amyloid Formation of AhHsp104 inhibits Aβ aggregation at different
stages of the fibrillization process
Thus far, the current results using purified Aβ
monomers and different aggregation states suggest
that Hsp104 interferes with Aβ fibrillization by
interacting with different aggregation intermediates
along the amyloid-formation pathway. It blocks the
fibrillization of monomeric and protofibrillar Aβ as
well as the reassociation and growth of fibrillar Aβ.Fig. 7. Hsp104 hinders Aβ aggregation at different stages o
time points of the aggregation process of monomeric Aβ alone
of the experiment (II) or after 4 h (III), 6 h (IV) and 9 h (V). T
standard deviations are plotted. (b) TEM images of the sameTo confirm these findings, the aggregation of mono-
meric Aβwas followed and the effect of introducing
Hsp104 at different time points during the fibrilliza-
tion process was probed. When Hsp104 was present
from the very beginning of the experiment (Fig.
7a-II) or added 4 h after the start of the incubation of
monomeric Aβ (Fig. 7a-III), no fibril formation was
observed by ThT and TEM during the course of the
experiment. Addition of Hsp104 at later time points
(6 and 9 h) resulted in an immediate inhibition off the aggregation process. (a) ThT fluorescence at different
(I), monomeric Aβwith Hsp104WT added at the beginning
he average fluorescence data from triplicate samples and
samples after 9 h of aggregation.
1168 Hsp104 Suppresses Amyloid Formation of Ahamyloid formation as discerned by the stabilization
of the ThT signal upon addition of Hsp104 (Fig. 7a-
IV and -V). In the latter cases, a sudden decrease in
ThT was consistently observed, but no further
decline in the ThT signal occurred even after the
Aβ-Hsp104 mixture was incubated for an additional
period of 40 h. The sudden decline in ThT signal
could be attributed to the strong binding of Hsp104
to Aβ aggregates and competition for ThT binding
sites. These findings are consistent with the results
obtained with purified protofibrillar and fibrillar Aβ
species (also visible in Supplementary Fig. S2) and
support the notion that Hsp104 interacts pre-
ferentially with aggregated forms of Aβ, including
protofibrils and fibrils, but does not promote
transitions from protofibrils or fibrils to monomers.
The fibrillization state, which stays “frozen” by the
addition of Hsp104, was monitored by TEM. Figure
7b demonstrates that the actual state of fibrillization
corresponds well to the different levels of ThT
fluorescence in the samples.
Binding of Aβ can be monitored by ATP turnover
of Hsp104 and by size-exclusion
chromatography co-elution
The aggregation assays shown above demon-
strate that ATP is not required for the inhibition of
Aβ aggregation by Hsp104, indicating a novel
nucleotide-independent interaction mechanism of
Hsp104. However, previous studies suggested that
Hsp104–substrate interaction is highly dependent
on its nucleotide state.4 Furthermore, substrate
binding in turn also influences the ATP turnover
by Hsp104.5 Consequently, the ATPase activity of
Hsp104 can be used as an indirect measure of
substrate binding. Accordingly, the ATP consump-
tion by Hsp104 in the presence of different con-Fig. 8. Influence of Aβ monomer on the ATP turnover
of Hsp104WT. ATP turnover of 0.2 μMHsp104 determined
in the presence of increasing concentrations of Aβ
monomer (♦) or Aβ protofibrils (●).centrations of monomeric and protofibrillar Aβwas
measured using a regenerative ATPase assay
system.34 Figure 8 shows that the addition Aβ to
Hsp104WT enhanced its ATPase activity in a
concentration-dependent manner. Monomeric Aβ
accelerated the ATPase activity of Hsp104 by a
factor of ∼2, whereas protofibrillar Aβ showed a
rather weak effect. The ATPase data suggest a direct
interaction between the two proteins and the
recognition of Aβ by Hsp104 as its substrate.
These findings are in good agreement with other
studies that show an acceleration of the Hsp104
ATPase activity upon binding of substrates such as
permanently unfolded RCMLA (reduced carboxy-
methylated α-lactalbumin).5,35 However, one study
by Schirmer and Lindquist showed a weak inhibi-
tion by Aβ42 with a reduction by a factor of 0.8.
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This discrepancy might be due to differences in the
aggregation state of Aβ or assay conditions such as
salt content, pH, the presence of traces of denatur-
ants (guanidinium chloride), and peptide concen-
tration, to which Hsp104 is highly sensitive.6,34
Beyond the ATPase assays, which are an indirect
measure of the substrate interaction, direct methods
were employed to study the binding of Aβ to
Hsp104. Size-exclusion chromatography (SEC)–
HPLC co-elution experiments were performed on
samples of Hsp104 in the presence and in the
absence of monomeric and protofibrillar Aβ. The
eluted fractions from the SEC columnwere analyzed
by a dot blot using antibodies against Aβ and
Hsp104, respectively (Fig. 9). In the first experiment,
a co-elution of Aβ monomer with the high mole-
cular weight species (corresponding to Hsp104) was
indicative of the interactions between Hsp104 and
Aβ. The dot blot shows that the Aβ monomer co-
eluted with Hsp104 in earlier fractions than the
sample containing Aβ monomer alone (Fig. 9a).
When Hsp104 was incubated with Aβ protofibrils
and injected into the column, the dot blot reveals
that a proportion of Hsp104 eluted earlier together
with the protofibrillar fractions. Consequently,
Hsp104 interacts with both monomeric and proto-
fibrillar forms of Aβ. However, it is important to
note that these experiments provide a qualitative
rather than a quantitative measure of the binding of
Hsp104 to Aβ. Interestingly, in both types of
experiments, binding of Hsp104 to Aβ monomer
and protofibrils, the addition of ATP, ADP, or ATPγS
did not influence the co-elution profile (data not
shown). This nucleotide-independent interaction
between Hsp104 and Aβ is in good agreement
with the results of the fibrillization assays described
above. The current co-elution experiment did not
show a complete binding of Aβ to Hsp104 but rather
a co-elution of a minor fraction of Aβmolecules with
Hsp104 (and vice versa for protofibrils), indicating a
transient substrate interaction. These results differ
from previous findings where co-elution of Hsp104
with its substrates (RCMLA, TrfA, α-casein, aggre-
gated glucose-6-phosphate dehydrogenase, and
β-galactosidase-derived peptides) was suggested
to be strictly dependent on the presence of non-
Fig. 9. Co-elution analysis of Hsp104WT with Aβ monomer (a), or Aβ protofibrils (b). Hsp104 (5 μM) was incubated
with (a) freshly prepared Aβmonomer (40 μM) or (b) Aβ PFs (100 μM) at room temperature for 30 min. Subsequently, the
samples were subjected to SEC–HPLC using a Superose 6 column. Fractions from SEC–HPLC were analyzed by dot blot
decorated with anti-Hsp104 or anti-Aβ antibodies.
1169Hsp104 Suppresses Amyloid Formation of Ahhydrolyzable ATP analogues or on the usage of the
mutant Hsp104TRAP.4,36–38Discussion
ClpB/Hsp104 proteins have the ability to mod-
ulate aggregate formation and toxicity and to
“catalyze” the disaggregation and recovery of
protein aggregates in yeast,12 Escherichia coli,39
mammalian cell cultures, and animal models of
HD and Parkinson's disease.16–20 Several mechan-
istic models have been proposed to explain these
experimental observations. These models include (i)
Hsp104-mediated inhibition of protein misfolding
and aggregation, (ii) diversion of proteins towards
non-toxic pathways, and (iii) disruption and dis-
sociation of prefibrillar and fibrillar toxic aggregates.
To better understand the mechanisms by which
Hsp104 modulates the aggregation of amyloid-
forming proteins, the effect of Hsp104 on the
different species along the amyloid fibril formation
pathway of Aβ42 was determined. Our findings
show that Hsp104 inhibits the fibrillization of
monomeric and protofibrillar forms of Aβ in aconcentration-dependent but ATP-independent
manner (Figs. 1–3). Strikingly, Hsp104 concentra-
tions as low as 0.01 μMwere sufficient to inhibit the
fibrillization of 10 μM monomeric Aβ (Fig. 2).
However, a highly efficient suppression of fibrilliza-
tion was found at Hsp104 concentrations of 1 μM: no
fibril formation was observed even after 10 days of
incubation at 37 °C (Fig. 2).
Hsp104 inhibition of Aβ fibrillization is observa-
ble up to stoichiometric ratios of 1:1000 (Hsp104/
Aβ, Fig. 2a-III), suggesting a preferential Hsp104
interaction with aggregation intermediates (e.g.,
oligomers, protofibrils, small fibrils) on the pathway
of Aβ amyloid formation. This hypothesis is con-
sistent with the current observations that Hsp104 (i)
interacts with Aβ protofibrils (Figs. 3c-IIIb and 9b),
(ii) inhibits conversion of protofibrils into amyloid
fibrils (Fig. 3), (iii) arrests fibril elongation and
reassembly (Fig. 6), and (iv) abolishes the capacity of
protofibrils and SFs to seed the fibrillization of
monomeric Aβ (Figs. 4 and 5). Together, these
findings suggest that the strong inhibition of Aβ
fibrillization by Hsp104 is mediated by its ability to
act at different stages and target multiple inter-
mediates on the pathway to amyloid formation
1170 Hsp104 Suppresses Amyloid Formation of Ah(Scheme 1c). Therefore, in addition to analyzing the
effect of Hsp104 on the fibrillization of purified Aβ
monomers, protofibrils, and fibrils, the ability of
Hsp104 to arrest Aβ fibrillization at various stages
along the fibrillization process, where a mixture of
these different structures is present, was investi-
gated. The addition of 1 μM Hsp104 at any time
point during the fibrillization process resulted in
complete inhibition and arrest of Aβ fibrillization as
discerned by ThT and TEM data (Fig. 7). Even when
Hsp104 was added during the exponential phase of
Aβ fibrillization, a complete arrest of fibril forma-
tion was observed. Interestingly, in none of these
samples a continuous decrease of ThT signal or an
increase in soluble Aβ species (monomers, oligo-
mers, protofibrils) was found, suggesting that
Hsp104 inhibits fibrillization and blocks fibril
elongation rather than mediates disaggregation of
Aβ amyloids. However, one could speculate that a
disaggregation activity only occurs if Hsp104 is
assisted by other chaperones, such as Hsp70/Hsp40,
which were not employed in this study.
In agreement with the current data reported here
for Aβ42, Inoue et al.
40 and Narayanan et al.41
demonstrated that Hsp104 inhibits fibrillization of
Sup35 fragments and Sup35NM in an ATP-inde-
pendent manner. However, Hsp104 is thought to
catalyze substrate unfolding by actively processing
polypeptides through the central pore of its hex-
americ form with a substrate binding state that
requires ATP or ATPγS.4,5,7,36 Thus, the nucleotide-
independent effect observed in the current work
suggests a different type of substrate interaction of
Hsp104 that results in an efficient inhibition of
amyloid fibril formation.
In vitro studies by Shorter and colleagues2,3
suggested that Hsp104 is a dual-function regulator
of protein fibrillogenesis; i.e., it has the capacity to (i)
catalyze amyloid formation and (ii) inhibit or
disrupt preformed fibrils. The primary switch
between the two opposing activities appeared to
be the concentration of Hsp104. At low concentra-
tions, Hsp104 was reported to catalyze the misfold-
ing and fibrillization of amyloid-forming proteins
such as the PrPs Sup35 and Ure2.2,22 The authors
proposed a general mechanism in which Hsp104
catalyzes fibrillization by fragmenting newly
formed amyloid fibrils, thus increasing the number
of fibrils ends and enhancing the seeding capacity of
these proteins. A similar mechanism has been
proposed to explain the role of Hsp104 in prion
propagation of yeast cells, where Hsp104 fragments
large insoluble prion aggregates into small prion
seeds that are transmitted to daughter cells upon
cell division.13,42–45 This hypothesis is supported by
the lack of polyQ aggregation in a yeast model of
HD and by prion loss in yeast strains lacking
Hsp104.13,46 The in vitro data presented in the
current study suggest that Hsp104 alone does not
exhibit a dual concentration-dependent mechanism
for modulating amyloid fibril formation; inhibition
instead of acceleration of amyloid formation by
Hsp104 was consistently observed. Interestingly, afusion protein of Sup35 and Aβ immediately
aggregates in yeast cells and the resulting chimeric
prion replicates independent of the presence of
Hsp104.47 These findings indicate that the mechan-
ism of action by Hsp104 is highly dependent on the
aggregation propensity of the substrate and differs
among amyloid-forming proteins.
Taken together, the current study demonstrates a
chaperoning activity of Hsp104 that contributes to
the disaggregation activity reported by others and
reveals a novel nucleotide-independent mechanism
of fibril formation inhibition. Hsp104 was found to
interact with different quaternary structures (mono-
mer, protofibrils, and fibrils) along the fibrillization
pathway of Aβ and inhibits their fibrillization
(Scheme 1c). Furthermore, it was demonstrated
that the inhibitory effect of Hsp104 is mediated by
its inhibition of protofibrils and fibrils growth and
self-assembly, rather than by Hsp104-induced dis-
assembly of Aβ aggregates and fibrils. These
mechanistic studies contribute significantly to our
understanding of the molecular mechanism under-
lying ClpB/Hsp104 proteins and possibly other
chaperones influencing amyloid formation and
toxicity and have important implications for the
prospects of using these molecules in future anti-
aggregation-based therapeutic strategies.Materials and Methods
Expression and purification of Hsp104
Hsp104WT and Hsp104TRAP were produced recombi-
nantly in E. coli BL21 cells and purified as described.34,48
Concentrations of Hsp104 were determined using an
extinction coefficient of ɛ276 nm=31,900M
−1 cm−1 and refer
to the monomeric species.
Monomeric and protofibrillar Aβ preparations
Aβ42 peptide was synthesized and purified by Dr.
James I. Elliott at Yale University (New Haven, CT) and
purity was assessed by reverse-phase HPLC and mass
spectrometry. To obtain monomeric Aβ, the peptide
was dissolved in 6 M urea at 1 mg/ml followed by
centrifugation in order to exclude insoluble material. The
supernatant was loaded onto a Superdex 75 HR 10/30
SEC column (GE Healthcare) previously equilibrated
with 10 mM Tris–HCl, pH 7.4, at a flow rate of 0.2 ml/
min. To obtain both protofibrillar and monomeric
fractions, a previously described protocol was followed.49
Briefly, the peptide was dissolved in 100% dimethyl
sulfoxide (DMSO) and adjusted to 1 mg/ml by adding
double-distilled water followed by pH adjustment with
2 M Tris, pH 7.4, such that final concentrations of
peptide, DMSO, and Tris were 200 μM, 5%, and 20 mM,
respectively. After centrifugation, the supernatant was
loaded onto a Superdex 75 HR 10/30 column. Peptide
concentration was estimated by UVabsorbance at 280 nm
in 10-mm path-length cuvettes using the theoretical molar
extinction coefficient at 280 nm (1490 M−1 cm−1).50 All
given SF and protofibril concentrations refer to mono-
meric protein.
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Aβ samples, in the presence or absence of Hsp104, were
incubated without agitation at 37 °C. The final concentra-
tions of Aβ and Hsp104 were 10 and 1 μM, respectively,
unless otherwise indicated. The final buffer composition
was 25 mM Tris, pH 7.6, 37.5 mM KCl, 2.5 mM MgCl2,
0.25% NaN3. When indicated, samples contained, in
addition, 5 mM ATP–Mg2+ or 1 mM ATPγS–Mg2+. For
the seeding experiments, first fibrils were generated by
incubation of 10–20 μMmonomeric Aβ at 37 °C for at least
96 h. The fibrils were then mechanically disrupted by
ultrasonication with a fine tip. The SFs, or seeds, were
added to the monomeric Aβ sample at a final concentra-
tion of 2.2 μM. Fibril formation and protein solubility was
monitored by ThT fluorescence, negative-staining TEM,
and SDS-PAGE as described below.
ThT binding assay
ThT binding assay was performed by mixing 10 μM
peptide solution with 10 μM ThT dye (Aβ/ThT ratio=1:1)
and 50 mM glycine–NaOH, pH 8.5 (final concentrations)
in Nunc384 well fluorescence plates (100 μl/well assay
volume). ThT fluorescence of each sample was measured
in an Analyst AD fluorometer (Molecular Devices) at
excitation and emission wavelengths of 450 and 485 nm,
respectively. The samples were analyzed in triplicates at
selected time points and average fluorescence values and
standard deviation were plotted.
Transmission electron microscopy
The samples (5–10 μl) were applied to carbon-coated
formvar 200-mesh grids (Electron Microscopy Sciences,
USA) and negatively stained with 2% uranyl acetate. EM
grids were visualized in a Philips CM-10 TEMmicroscope
at 100 kV and image acquisition was performed with a
Morada TEM camera using iTEM 5 software (Olympus
Soft Imaging Solutions).
SDS-PAGE analysis
To quantify the amount of Aβ remaining soluble in the
samples, 50-μl aliqots were centrifuged at 13,200 rpm for
5 min and the supernatant was loaded onto 15% poly-
acrylamide gels under denaturing conditions. Silver
staining (SilverXpress Silver Staining Kit, Invitrogen)
was applied in order to detect the protein bands with a
higher sensitivity.
ATPase assays
ATP hydrolysis by Hsp104 was monitored using a
coupled enzymatic assay with an ATP-regenerating
system consisting of PK and PEP as well as lactate dehy-
drogenase and NADH/H+, as previously described.34
Assays were performed at 30 °C in assay buffer (25 mM
Tris, pH 7.6, 37.5 mM KCl, 8 mM MgCl2, 0.25% NaN3)
containing 5 mM ATP and 0.2 μM Hsp104. Each ATPase
experiment was started by monitoring the absorbance of
NADH at 340 nm including all assay components except
Hsp104. When the signal was settled as a flat line, the
reaction was started by the addition of Hsp104.The ATP
turnover of Hsp104 was determined from the slope
dA340 nm/dt using a molar absorbance coefficient forNADH of ɛ340 nm=6200 M
−1 cm−1 as described.5 For each
data point, three independent measurements were carried
out to calculate the mean and the standard deviation for
each sample set.
SEC–HPLC co-elution experiments
Samples containing 5 μM Hsp104WT, with or without
40 μM Aβ monomer, or 100 μM Aβ protofibrils were
prepared in 25 mMTris, pH 7.6, 37.5 mMKCl, and 2.5 mM
MgCl2 and incubated at 25 °C for 30min. A sample of 35 μl
was separated at a flow rate of 0.08 ml/min on a Superose
6 PC3.2/30 column (GE Healthcare) equilibrated with the
sample buffer described above. The absorbance of the
proteins was monitored at 214 nm and fractions were
collected every minute. For dot blot analysis, 1.8 μl of each
fraction was placed on a membrane and visualized using
anti-Hsp104 antibodies (rabbit) or anti-Aβ antibodies
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